10374-51-3Relevant articles and documents
Asymmetric Bayer-Villiger oxidation of cyclobutanones
Lopp, Margus,Paju, Anne,Kanger, Tonis,Pehk, Tonis
, p. 7583 - 7586 (1996)
The asymmetric Baeyer-Villiger oxidation of racemic cyclobutanones 1, 2, and 3 and a prochiral cyclobutanone 4 under Sharpless oxidation conditions resulted in the enantiomeric lactones 5 ee 34%, 6 ee 53%, 7 ee 75% and 8 40% ee respectively.
THE TRANSFORMATION OF ALKENES INTO γ-LACTONES USING α-IODOESTERS
Kraus, George A.,Landgrebe, Kevin
, p. 3939 - 3942 (1984)
Iodostannyl esters react with alkenes in the presence of AIBN to afford γ-lactones.
Radical addition of 2-iodoalkanamide or 2-iodoalkanoic acid to alkenes with a water-soluble radical initiator in aqueous media: Facile synthesis of γ-lactones
Yorimitsu,Wakabayashi,Shinokubo,Oshima
, p. 1963 - 1970 (2001)
Radical reactions in water or aqueous ethanol using a water-soluble radical initiator are described. Heating a mixture of 2-iodoacetamide and 5-hexen-1-ol in water at 75 °C in the presence of a water-soluble radical initiator, 4,4′-azobis 4-cyanopentanoic acid), afforded 5-(4-hydroxybutyl)dihydrofuran-2(3H)-one in 95% yield. The use of 2-iodoacetic acid in place of 2-iodoacetamide also gave the same γ-lactone in 93% yield. The reaction of 2-iodoacetamide with 1-octene in aqueous ethanol was initiated by 2,2′-azobis(2-methylpropanamidine) dihydrochloride to provide γ-decanolactone. Employing water as a solvent is crucial to obtain lactone in satisfactory yield.
Heterogeneous Permanganate Oxidation of 1,5-Dienes: A Novel Synthesis of 5-Substituted Butanolides
Baskaran, Sundarababu,Islam, Imadul,Vankar, Padma S.,Chandrasekaran, Srinivasan
, p. 626 - 627 (1992)
In the presence of a catalytic amount of water, 1,5-dienes undergo novel and unusual oxidation with potassium permanganate-copper sulfate in dichloromethane to give substituted butanolides in good yields under very mild conditions.
-
Nikishin et al.
, (1972)
-
Method for preparing 5-hydroxymethyldihydrofuran-2-one by taking furfural as raw material
-
Paragraph 0022-0027, (2020/07/02)
The invention discloses a method for preparing 5-hydroxymethyldihydrofuran-2-one by using furfural as a raw material, and relates to a preparation method of an organic chemical raw material. The method is as follows: furfural is used as a raw material, ethanol is used as a solvent, a Raney nickel catalyst is used, and tetrahydrofurfuryl alcohol is prepared by catalytic hydrogenation reduction; gamma-Al2O3 is taken as a carrier, cerium nitrate and silver nitrate are taken as raw materials, and an Ag/CeO2/Gamma-Al2O3 catalyst is prepared by adopting an impregnation method, a roasting method anda natural cooling method; and the prepared tetrahydrofurfuryl alcohol is used as a raw material, the prepared Ag/CeO2/gamma-Al2O3 catalyst is adopted, and oxygen is introduced for a reaction to obtain5-hydroxymethyl dihydrofuran-2-one. The method is beneficial to improving the product selectivity; the catalyst is prepared by adopting a dipping-roasting method, the method is simple, the dispersityof active metal elements is good, and the product selectivity is high; and the product 5-hydroxymethyldihydrofuran-2-one has hydroxyl, furan ring and keto functional groups, is a raw material for synthesizing a plurality of antiviral, anticancer and anti-AIDS medicines, and has the advantages of high added value, high economic benefit and high social benefit.
NITRIC OXIDE-RELEASING PRODRUG MOLECULE
-
Paragraph 0079, (2018/08/01)
Provided are a type of compounds that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.